Neuraptive Therapeutics Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX001 for the Adjunct Treatment of Transected Peripheral Nerves

Neuraptive Therapeutics Inc. a leader in nerve repair and regeneration is pleased to announce a significant milestone in transforming the treatment paradigm for peripheral nerve injuries.

Related Keywords

Michigan ,United States ,Evan Tzanis ,Robert Radie ,Neuraptive Therapeutics Inc ,Chief Operating Officer ,Neuraptive Therapeutics ,Business Wire ,Evaluator Blinded Study ,Treatment Emergent Adverse Events ,Serious Adverse Events ,Michigan Hand Questionnaire ,Numeric Pain Rating Scale ,Semmes Weinstein Monofilament Test ,Patient Global Impression ,Week Results ,Total Score ,Secondary Endpoints ,Edge Mechanism ,Leading Experts ,Clinical Trials ,Media Contact ,Neuraptive Therapeutics Inc The Neurofuse Study Ntx001 Transected Peripheral Nerves Evan Tzanis Robert Radie Pegfusion Clinical Trials ,